The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. has introduced its latest modifier gene therapy platform aimed at treating inherited retinal and blindness diseases, presenting the technology at three major conferences this month.
The company’s participation underscores a growing interest in next-generation therapies for vision loss. Ocugen’s innovation focuses on genetic conditions with significant unmet needs, positioning the company at the forefront of ophthalmic research. Investors and industry stakeholders continue to monitor developments, given the potential impact on future treatment paradigms.
Ocugen is also pursuing gene therapies for inherited retinal conditions, including early-stage development for Stargardt disease, which affects an estimated 100,000 patients without FDA approved treatment options (read more). The company recently completed trial enrollment for its OCU400 and OCU410ST programs. Ocugen projects its cash runway will extend into 2028 following positive OCU410 data (details here).